Skip to main content
NCBI home page
Portland Press Open Access logoLink to Portland Press Open Access
. 2021 Nov 26;65(6):1015–1024. doi: 10.1042/EBC20210038

Colon cancer checks in when bile acids check out: the bile acid–nuclear receptor axis in colon cancer

Qin Tang 1, Ronald M Evans 1,✉
PMCID: PMC8628182  PMID: 34414429

Abstract

Bile acids (BAs) are a class of hepatically derived metabolite-hormones with prominent roles in nutrient absorption, metabolic and immune homeostasis in the intestine. BAs are ligands for multiple nuclear receptors (NRs), through which they confer transcriptional regulation on target genes that form an enterohepatic hormonal feedback loop to regulate BA synthesis and maintain lipid homeostasis. Endogenous BAs made by the host undergo significant biotransformation by the gut microbiota in the intestine, which diversifies the intestinal BA pool and facilitate host–microbiota cross-talk through BA-mediated signaling. BAs dysregulation contributes to development of metabolic diseases, pathological inflammation and colon cancer. This review provides a brief historic perspective of the study of NR-mediated BA signaling transduction, with a focus on recent advancements in understanding the active role the gut microbiome plays in reshaping intestinal BA landscape, and the implications of novel microbially derived BAs in modulating immune homeostasis and cancer development in the host. Targeting the BA–NR signaling axis for pharmacological intervention provides ample opportunities in the prevention and treatment of intestinal diseases.

Keywords: bile acid, colon cancer, colorectal cancer, FXR

Introduction

Colorectal cancer (CRC) affects over 140 000 patients annually in the United States and is currently the second leading cause of cancer-related deaths [1]. The etiology of CRC is complex, but research in the past few decades has clearly indicated that genetic, dietary and lifestyle factors affect development and progression of CRC. The most significant genetic factor in hereditary risk for CRC is loss-of-function mutations in the adenomatous polyposis coli (APC) tumor suppressor gene [2]. Studies dating back to the 1970s have reported that risk for developing CRC was much higher among Japanese individuals who converted into a low-fiber and high-fat ‘Western’ diet after immigration to the United States [3,4]. Since then, the prevalence of unhealthy dietary habits has been linked to rising incidence of CRC worldwide [5]. A recent alarming trend is that CRC risk is rapidly increasing (1–3% annually) in adults younger than 50 years in the United States [1]. In light of these evidence, the U.S. Preventative Services Task Force has issued a recommendation to start routine screenings for CRC at the age of 45, to increase early diagnosis and treatment, and curb CRC-related deaths [6].

In humans and mice, bile acids (BAs) are a class of steroid acids abundant in the bile. They are produced from cholesterol metabolism in the mammalian liver [7]. From 1950s to 1970s, research on the structure and function of BAs led by Hofmann [8] and others noted the amphipathic nature of BA molecules, and argued that they play a decisive role in facilitating lipid and vitamin absorption in the intestine [9]. In fact, BAs emulsify lipids so well that they have been medically administered in patients for dissolution of cholesterol stone in the gallbladder [10,11]. The 1980s saw an uptick in interest in BAs in the medical community, with reports implicating perturbations in BA metabolism in liver [12,13] and intestinal diseases [14,15] as well as cancer [16,17]. In the 1990s, major physiological functions of BAs were established. Briefly, BAs are synthesized in the liver, stored in the gallbladder and released into the small intestine through the bile duct. Following intestinal transit, most BAs are reabsorbed in the terminal ileum to the hepatic portal vein and trafficked back to the liver. Hepatic production of BAs and the total amount of BAs in enterohepatic circulation fluctuate significantly with respect to dietary lipid intake. BAs undergo enterohepatic circulation several times each day. Through enterohepatic circulation, BAs confer negative feedback regulation on lipid metabolism (in particular, cholesterol biosynthesis), and have pivotal roles in the regulation of glucose metabolism [18–22].

A signaling molecule disguised as a detergent

In 1995, the Evans lab reported the isolation of an orphan receptor that forms a heterodimer with the retinoid X receptor (RXR) [23]. This work identified farnesol and related metabolites as potent activators of the complex. Farnesol is the chemical precursor to BAs, and the discovery in 1999 that BAs were potent farnesoid X receptor (FXR) ligands [24] redefined them as an unrecognized class of hormonal ligands. In the next few decades, research led by Chiang, Makishima et al., Russell and Setchell, Schoonjans et al. among others laid the foundation of contemporary understanding of BA physiology. There are a number of excellent reviews on this topic [25–30] that we encourage readers to seek out in order to get a panoramic view of research in this field. Very briefly, the first and only rate-limiting step in classic hepatic BA synthesis is catalyzed by the cholesterol 7α-hydroxylase (CYP7A1) that converts the cholesterol into 7α-hydroxycholesterol [31,32]. The liver also frequently conjugates BAs with glycine or taurine through a reaction catalyzed by the BA-CoA:amino acid N-acyltransferase (BAAT) prior to their release into the small intestine [33–35]. In humans, cholic acid (CA), chenodeoxycholic acid (CDCA) and their tauro- or glyco-derivatives make up the majority of BAs in circulation. There are two major classes of receptors for BAs in the intestine: the G-protein-coupled receptors (most notably TGR5 encoded by the GPBAR1 gene) [36,37], or nuclear receptors (NRs) [24,38–40]. TGR5–BA interactions in health and disease have been extensively reviewed elsewhere [41,42]. In this review, we focus on NRs, a unique class of ligand-responsive transcriptional factors, which differs from surface receptors in their ability to enter the nucleus of the cell and mediate transcriptional regulation. Specifically, ligand-unbound NRs are typically retained within the cytosol; binding to ligands induces conformational changes in NRs and induce their translocation to the cell nucleus, where it binds at specific regulatory elements in the genomic DNA, and coordinate changes in transcriptional output of target genes through recruitment of transcriptional co-activators or co-repressors. Of multiple BA-responsive NRs reported in the literature, the FXR (encoded by NR1H4) is considered a master regulator of BAs in the gastrointestinal system.

Work in the late 1990s into the 2000s led by our group, Forman, Gonzalez, Mangelsdorf, Kliewer, Moore and many others uncovered that FXR is the cognate NR for CDCA [43], and revealed the molecular underpinnings of the BA–FXR signaling axis [44–49]. Briefly, cellular uptake of CDCA through the apical sodium bile salt transporter (ASBT) activates FXR in ileal epithelial cells, leading to its heterodimerization with RXR, translocation to the nucleus and binding to FXR response element (FXRE) therein. Transcription of two small peptide hormones, the human fibroblast growth factor (FGF) 19 (or its murine ortholog Fgf15), are up-regulated. FGF15/19 subsequently traffic back to the liver, initiating a signaling cascade involving the induction of small heterodimer partner 1 (SHP-1; NR0B2) and recruitment of liver receptor homolog 1 (LRH-1; NR5A2) to the CYP7A1 promoter [50,51]. This confers transcriptional repression of CYP7A1 and, consequently, mediates suppression of hepatic BA synthesis. Thus, BA levels are under negative-feedback control through the enterohepatic FXR-FGF15/19 signaling axis (Figure 1). In addition to FXR, other NRs including vitamin D receptor (VDR) [39], pregnane X receptor (PXR, encoded by NR1I2) [38], constitutive androstane receptor (CAR, encoded by NR1I3) [40] and the retinoic acid-related orphan receptor γ (RORγ, encoded by NR1F3) [52,53] can also respond to BAs, the details of which will be discussed later. Of these, NRs are differentially expressed in different segments of the gastrointestinal tract. Notably, FXR expression is the highest in the mouse ileum, consistent with the highest activity of BA reabsorption in this segment of the small intestine (Figure 2). Lastly, the liver X receptor (LXR), the master regulator of cholesterol metabolism in the liver, confers opposing effects of transcriptional regulation on CYP7A1 with FXR, constituting a dual network that balances the ‘yin’ and ‘yang’ of lipid metabolism [47,48]. The contemporary view holds BAs not only as molecular detergents that facilitate lipid absorption, but also metabolite-hormones that serve as signaling molecules in the digestive system [27,29].

Figure 1. The enterohepatic circulation of BAs and signaling transduction through BA-responsive receptors in the intestine.

Figure 1

Open in a new tab

Figure 2. RNA expression of major BA-sensing NRs in the mouse intestine.

Figure 2

Open in a new tab

BA diversity, a gut microbiome production

In recent years, it has been increasingly appreciated that the gut microbiome is an integral part of intestinal homeostasis and health [54,55]. While the majority of hepatically derived BAs are reabsorbed and recycled in the ileum, a small proportion (5%) comes into contact with the gut microbiome in the distal ileum, cecum and colon. The microbiome confers substantial biotransformation on host liver-derived BAs; the resultant microbially derived BAs are termed ‘secondary’ BAs to differentiate from host-derived ‘primary’ BAs [56–58]. Human gut microbiota is dominated by Firmicutes, Bacteroidetes and Actinobacteria [59]. Many of these species have specialized enzymes to modify the cholesterol backbone or deamidate glycine or taurine-conjugated primary BAs [60,61]. One particular microbially catalyzed BA transformation is 7α-dehydroxylation, which produces dominant secondary BAs deoxycholic acid (DCA, from CA) and lithocholic acid (LCA, from CDCA) [62,63]. Recently, six new microbial enzymes necessary and sufficient for the conversion of CA into DCA have been identified [64], establishing a complete roadmap from a primary BA to its secondary BA derivative.

The gut microbiota changes swiftly in response to environmental factors [65], particularly to the influence of diet [66]. Dietary perturbation could alter the composition of the gut microbiome and disrupt the balance between beneficial and detrimental gut microbiota [67,68], resulting in impaired host metabolic and immune homeostasis [69] that can set the stage for disease development [70]. BAs can alter the gut microbiota composition by forming an intestinal microenvironment favorable to the survival and proliferation of certain microbes, at the expense of others. For example, obeticholic acid, a synthetic BA analog and FXR agonist, confers growth advantage on Firmicutes in the small intestine [71]. In inflammatory bowel disease (IBD) patients, the structure of the gut microbiota is significantly altered compared with healthy individuals [72,73], concurrent with reported disruption in BA metabolism [74]; both are thought to significantly contribute to pathogenesis and disease progression. Moreover, microbial biotransformation of BAs also significantly enriches the endogenous BA repertoire in the host [75]. Recent advancement in new techniques, particularly high-throughput LC–MS/MS mass spectrometry and 16S rRNA gene sequencing, allowed investigators to efficiently probe the diversity of secondary BAs in the mammalian gut. Capitalizing on these techniques, Dorrestein et al. [76] conducted comprehensive profiling of metabolome in the mammalian gastrointestinal tract. By comparing BA profiles in germ-free versus specific pathogen-free mice, they uncovered several previously unknown secondary BAs, including a unique class of phenylalanine or tyrosine-conjugated BAs on a cholate backbone [76]. Intriguingly, these novel secondary BAs activate FXR signaling in vitro, warranting further investigation on their functions in modulating the host BA–FXR signaling axis. The consensus now is that the gut microbiome actively participates in shaping the BA landscape in the mammalian gut, and regulate host health through the production of secondary BAs that engage host NRs to facilitate host–microbiome cross-talk.

Our deepening understanding of the gut microbiome and continuing characterization of secondary BAs also expanded our knowledge of BA-responsive NRs beyond FXR. Work by our group and the Kliewer group showed that VDR, PXR and its human homolog steroid and xenobiotic receptor (SXR) are receptors for LCA, one of the most abundant secondary BAs; activation of these NRs induces production of CYP3A in the liver to catabolize excess LCA, thereby conferring protection against liver toxicity [38,39,77]. VDR and PXR also participate in the enterohepatic BA–FGF15/19–CYP7A1 negative feedback loop to control BA synthesis in the liver [78,79] (Figure 1).

At the crossroads of good and evil

The FXR gene has characteristics of a tumor suppressor in colon cancer. FXR knockout mice under carcinogen challenge had increased intestinal epithelial cell proliferation and tumor development [80]. In human CRC patients, low expression of FXR is correlated with poor prognosis [81]. By comparing human CRC samples, precancerous polyps and normal tissue, Bailey et al. showed that the NR1H4/FXR promoter is methylated in ∼12% of human colon cancer samples, contributing to epigenetic silencing of FXR expression in the early stages of human colon cancer development [82]. Together, these data supported that FXR down-regulation is an important event in CRC initiation, and suggested that activation of FXR in intestinal tissues could prevent or curb progression of colon cancer.

BA dysregulation is a hallmark of CRC development [83]. Conventional wisdom dictates that BAs as surfactants are disruptive of the lipid bilayer of the cell membrane; therefore, aberrantly high levels of BAs are considered cytotoxic to intestinal epithelial cells and enterocytes. This notion is supported by multiple reports that prolonged exposure to aberrantly high levels of BAs poses elevated risk for the development of CRC [84–86]. Fecal levels of secondary BAs in human patients also correlate with mucosal and metabolic markers of CRC [87]. A recent study conducted by our group showed that, in CRC mouse models, HFD increases intestinal BAs as well as CRC incidence. Specifically, in the CRC (ApcMin/+) mouse model, HFD triggers a 60-fold increase in tauro-β-muricholic acid (T-βMCA, a secondary BA). T-βMCA was shown to be a potent antagonist of FXR in ileal epithelial cells as well as promoting DNA damage in Lgr5-expressing CRC stem cells. As a consequence of these changes, T-βMCA (like HFD) was sufficient to promote adenoma-to-adenocarcinoma transformation and accelerate CRC disease progression. Conversely, activation of FXR signaling by oral delivery of a gut-restricted FXR agonist (termed FexD), effectively curtailed tumor progression and prolonged survival [88]. This work lends support for the notion that the gut microbiome substantially modulates cancer development by the BA–NR signaling axis in the host, highlighting the potential of sustained FXR activation to curtail CRC development (Figure 3).

Figure 3. BA dysregulation and its implications in CRC development.

Figure 3

Open in a new tab

CRC develops at a unique site of peripheral immunity facilitated by localized chronic inflammation [89]. The gut-associated lymphoid tissue (GALT), including lamina propria (LP), intraepithelial lymphocytes, Peyer’s patches and the mesenteric lymph node, provides a prime interface with the gut microbiome as well as mediating immune education and tolerance [90,91]. Both FXR and TGR5 are expressed in intestinal and liver innate immune cell types [92]. Public data from the Immunological Genome Project [93] also confirmed expression of multiple NRs in T cells and innate lymphoid cells (ILCs) isolated from the mouse intestine. This provides a unique way for BA sensors in immune cells to impact intestinal immune homeostasis as well as intestinal carcinogenesis [94]. A number of secondary BAs that suppress FXR and PXR signaling in IBD patients during disease progression have been identified [95,96]. Habtezion et al. recently reported that Ruminococcaceae, one of few taxa known to include secondary BA-producing bacteria, was substantially depleted in ulcerative colitis (UC) patients [97]. Studies in mouse models showed that DCA, a secondary BA increased by Western diet, contributed to impairment of the intestinal barrier and exacerbated tumor progression in ApcMin/+ mice through FXR-dependent mechanisms [98,99].

Recently, a quartet of high-profile papers revealed diverse molecular mechanisms by which the microbial BA–NR axis confers regulation on intestinal immune homeostasis in the host. Song et al. showed that the abundant secondary BA LCA and its derivative 3-oxoLCA were required for induction of colonic RORγ+ Treg cells in mice. Taking a mouse genetics approach, they confirmed that VDR was required in this process, implicating the BA–VDR axis in the establishment of colonic immune tolerance [53]. Hung et al. also reported that two distinct derivatives of LCA, 3-oxo-LCA and isoalloLCA, affected intestinal T-cell lineage specification, albeit through different mechanisms. In vitro studies showed that 3-oxoLCA inhibited IL-17a+ Th17 cell differentiation by suppression of the lineage defining transcription factor RORγt, while isoalloLCA induced Foxp3+ Treg cell differentiation through mitochondrial redox-related mechanisms [52]. Campbell et al. reported that another secondary BA, 3β-hydroxydeoxycholic acid (isoDCA), increased Foxp3+ Treg cell induction in the colonic LP. Interestingly, this effect required the presence of antigen-presenting cells, i.e. dendritic cells (DCs) in vitro. Subsequent studies in DC-specific FXR knockout mice (Csf1rCreNr1h4fl/fl) confirmed that FXR signaling in DCs was indispensable for isoDCA-mediated Treg cell induction in vivo. The present study culminated in the design of an isoDCA-producing artificial microbiota capable of increasing the number of colonic Treg cells in mice [100]. Chen et al. showed that the nuclear xenobiotic receptor CAR (Nr1i3) also has a role in establishing mucosal immune cell tolerance of high BA concentrations in the ileum, the prominent site for BA reabsorption. In vivo studies showed that CAR coordinated up-regulation of the xenobiotic transporter MDR1 gene in CD4+ T effector cells in small intestinal LP to prevent BA toxicity and suppress inflammation [101]. Lastly, our group reported that pharmacological FXR activation suppressed production of pro-inflammatory cytokines IL17 and IL6 in type 3 ILCs (ILC3) in the small intestinal LP, and protected against intestinal inflammation in a chemically induced IBD mouse model [102]. In sum, these works highlight the roles of the BA–NR axis as a pivotal regulator for intestinal immune homeostasis.

In this review, we covered previously unexpected aspects of BA metabolism, their emerging roles in physiology, and offered an NR-centric view of the molecular mechanisms underlying response to BA-mediated signaling in the enterohepatic system. Multiple NRs, including but not limited to FXR, VDR, PXR, CAR and RORγ are concurrent sensors for BAs and critical components in an expansive signaling network that govern intestinal metabolic and immune homeostasis. Importantly, as NRs, they provide druggable targets for intervention in metabolic disorders and intestinal tumorigenesis. Understanding the dynamic interplay between dietary risk factors and the gut microbiota in healthy and diseased states hold promise for the development of novel methods for the prevention and treatment of CRC. Future work on secondary BAs and NR signaling could provide insight in biological mechanisms underlying host–commensal cross-talk and facilitate deeper understanding of how gut microbiome regulate host metabolism and immunity. Knowledge gained in these efforts could also guide the development of novel non-invasive approaches for engineering the commensal ecosystem to treat and prevent metabolic diseases and gastrointestinal cancers.

Summary

  • BAs are metabolite-hormones in enterohepatic circulation with prominent roles in lipid absorption, metabolic and immune homeostasis.

  • The intestine harbors a diverse pool of host liver-derived as well as gut microbiome-transformed BAs, which serve as an unrecognized vehicle for host–microbiome cross-talk.

  • BAs acting on innate and adaptive cell functions play important roles in maintaining immune homeostasis in the gut. BA dysregulation contributes to the inflammatory pathogenesis and drives tumorigenesis.

  • The ligand-responsive nature of NRs provides unique opportunities pharmacological intervention in the treatment of diseases.

Acknowledgements

We thank H. Wang and W. Fan for critical reading of the manuscript, L. Ong and C. Brondos for administrative assistance. Figures are created with BioRender.com.

Abbreviations

APC

adenomatous polyposis coli

BA

bile acid

CA

cholic acid

CAR

constitutive androstane receptor

CDCA

chenodeoxycholic acid

CRC

colorectal cancer

CYP7A1

cholesterol 7α-hydroxylase

DC

dendritic cell

DCA

deoxycholic acid

FGF

fibroblast growth factor

FXR

farnesoid X receptor

HFD

high-fat diet

IBD

inflammatory bowel disease

ILC

innate lymphoid cell

isoDCA

3β-hydroxydeoxycholic acid

LCA

lithocholic acid

LP

lamina propria

NR

nuclear receptor

PXR

pregnane X receptor

RORγ

retinoic acid-related orphan receptor γ

RXR

retinoid X receptor

T-βMCA

tauro-β-muricholic acid

Treg

regulatory T cells

VDR

vitamin D receptor

Competing Interests

Q.T. declares no conflicts of interest. RME is a founder of Mitobridge Inc., Metacrine Pharmaceuticals and Syndax Pharmaceuticals and a consultant to Amgen. R.M.E. declares no conflict of interest associated with this manuscript.

Funding

Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R01DK057978, the National Cancer Institute of the National Institutes of Health under Award Number CA014195, the National Institute Of Environmental Health Sciences of the National Institutes of Health under Award Number P42ES010337, and a SWCRF Investigator Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. R.M.E is the March of Dimes Chair in Molecular and Developmental Biology and a NOMIS Foundation Distinguished Scientist and Scholar at the Salk Institute.

Author Contribution

Q.T. interpreted data, prepared figures, and drafted the manuscript. R.M.E. edited and revised the manuscript. Both authors approved the final version of the manuscript.

References

  • 1.Siegel R.L., Miller K.D., Goding Sauer A., Fedewa S.A., Butterly L.F., Anderson J.C.et al. (2020) Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70, 145–164 10.3322/caac.21601 [DOI] [PubMed] [Google Scholar]
  • 2.Fodde R. (2002) The APC gene in colorectal cancer. Eur. J. Cancer 38, 867–871 10.1016/S0959-8049(02)00040-0 [DOI] [PubMed] [Google Scholar]
  • 3.Bingham S.A., Day N.E., Luben R., Ferrari P., Slimani N., Norat T.et al. (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361, 1496–1501 10.1016/S0140-6736(03)13174-1 [DOI] [PubMed] [Google Scholar]
  • 4.Wynder E.L. and Reddy B.S. (1974) Metabolic epidemiology of colorectal cancer. Cancer 34, 801–806 [DOI] [PubMed] [Google Scholar]
  • 5.Slattery M.L., Boucher K.M., Caan B.J., Potter J.D. and Ma K.N. (1998) Eating patterns and risk of colon cancer. Am. J. Epidemiol. 148, 4–16 10.1093/aje/148.1.4-a [DOI] [PubMed] [Google Scholar]
  • 6.Force U.S.P.S.T., Davidson K.W., Barry M.J., Mangione C.M., Cabana M., Caughey A.B.et al. (2021) Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 10.1001/jama.2021.6238 [DOI] [PubMed] [Google Scholar]
  • 7.Monte M.J., Marin J.J., Antelo A. and Vazquez-Tato J. (2009) Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804–816 10.3748/wjg.15.804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hofmann A.F. (1999) Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14, 24–29 10.1152/physiologyonline.1999.14.1.24 [DOI] [PubMed] [Google Scholar]
  • 9.Papp J.P. (1972) Bile salts in health and disease. Mich. Med. 71, 865–869 [PubMed] [Google Scholar]
  • 10.LaRusso N.F. and Thistle J.L. (1983) Effect of litholytic bile acids on cholesterol absorption in gallstone patients. Gastroenterology 84, 265–271 10.1016/S0016-5085(83)80121-8 [DOI] [PubMed] [Google Scholar]
  • 11.Cheung L.Y., Englert E. Jr, Moody F.G. and Wales E.E. (1974) Dissolution of gallstones with bile salts, lecithin, and heparin. Surgery 76, 500–503 [PubMed] [Google Scholar]
  • 12.Shaffer E.A. and Gordon E.R. (1978) Serum bile acids as related to bile acid secretion in liver disease. Am. J. Dig. Dis. 23, 392–397 10.1007/BF01072920 [DOI] [PubMed] [Google Scholar]
  • 13.Akamatsu K., Tanaka A. and Taketa K. (1977) Studies of serum bile acid determination by enzyme method and serum total bile acid in liver diseases. Nihon Shokakibyo Gakkai Zasshi 74, 340–350 [PubMed] [Google Scholar]
  • 14.Chadwick V.S. and Camilleri M. (1981) Role of bile acids in the pathogenesis of diarrhoea in various diseases. Acta Gastroenterol. Belg. 44, 43–48 [PubMed] [Google Scholar]
  • 15.Matsuzaki S., Imawari M., Mitamura K., Osuga T. and Sakita T. (1982) Measurement of serum individual bile acid in intestinal diseases. Nihon Shokakibyo Gakkai Zasshi 79, 1488. [PubMed] [Google Scholar]
  • 16.Cheah P.Y. and Bernstein H. (1990) Colon cancer and dietary fiber: cellulose inhibits the DNA-damaging ability of bile acids. Nutr. Cancer 13, 51–57 10.1080/01635589009514044 [DOI] [PubMed] [Google Scholar]
  • 17.Thornton J.R. (1979) Cholesterol and colon cancer. Lancet 1, 971 10.1016/S0140-6736(79)91739-2 [DOI] [PubMed] [Google Scholar]
  • 18.Rajani C. and Jia W. (2018) Bile acids and their effects on diabetes. Front. Med. 12, 608–623 10.1007/s11684-018-0644-x [DOI] [PubMed] [Google Scholar]
  • 19.Fang S., Suh J.M., Reilly S.M., Yu E., Osborn O., Lackey D.et al. (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159–165 10.1038/nm.3760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Prawitt J., Caron S. and Staels B. (2011) Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr. Diabetes Rep. 11, 160–166 10.1007/s11892-011-0187-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Prawitt J. and Staels B. (2010) Bile acid sequestrants: glucose-lowering mechanisms. Metab. Syndr. Relat. Disord. 8, S3–S8 10.1089/met.2010.0096 [DOI] [PubMed] [Google Scholar]
  • 22.Claudel T., Staels B. and Kuipers F. (2005) The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25, 2020–2030 10.1161/01.ATV.0000178994.21828.a7 [DOI] [PubMed] [Google Scholar]
  • 23.Forman B.M., Umesono K., Chen J. and Evans R.M. (1995) Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81, 541–550 10.1016/0092-8674(95)90075-6 [DOI] [PubMed] [Google Scholar]
  • 24.Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A.et al. (1999) Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 10.1126/science.284.5418.1362 [DOI] [PubMed] [Google Scholar]
  • 25.Russell D.W. and Setchell K.D. (1992) Bile acid biosynthesis. Biochemistry 31, 4737–4749 10.1021/bi00135a001 [DOI] [PubMed] [Google Scholar]
  • 26.Thomas C., Pellicciari R., Pruzanski M., Auwerx J. and Schoonjans K. (2008) Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678–693 10.1038/nrd2619 [DOI] [PubMed] [Google Scholar]
  • 27.Chiang J.Y. (2013) Bile acid metabolism and signaling. Compr. Physiol. 3, 1191–1212 10.1002/cphy.c120023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hofmann A.F. and Hagey L.R. (2014) Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J. Lipid Res. 55, 1553–1595 10.1194/jlr.R049437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Li T. and Chiang J.Y. (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66, 948–983 10.1124/pr.113.008201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chiang J.Y. (2017) Recent advances in understanding bile acid homeostasis. F1000Res. 6, 2029 10.12688/f1000research.12449.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Cohen J.C., Cali J.J., Jelinek D.F., Mehrabian M., Sparkes R.S., Lusis A.J.et al. (1992) Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12. Genomics 14, 153–161 10.1016/S0888-7543(05)80298-8 [DOI] [PubMed] [Google Scholar]
  • 32.Wang D.P. and Chiang J.Y. (1994) Structure and nucleotide sequences of the human cholesterol 7 alpha-hydroxylase gene (CYP7). Genomics 20, 320–323 10.1006/geno.1994.1177 [DOI] [PubMed] [Google Scholar]
  • 33.Johnson M.R., Barnes S., Kwakye J.B. and Diasio R.B. (1991) Purification and characterization of bile acid-CoA:amino acid N-acyltransferase from human liver. J. Biol. Chem. 266, 10227–10233 10.1016/S0021-9258(18)99213-6 [DOI] [PubMed] [Google Scholar]
  • 34.Falany C.N., Johnson M.R., Barnes S. and Diasio R.B. (1994) Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J. Biol. Chem. 269, 19375–19379 10.1016/S0021-9258(17)32178-6 [DOI] [PubMed] [Google Scholar]
  • 35.O’Byrne J., Hunt M.C., Rai D.K., Saeki M. and Alexson S.E. (2003) The human bile acid-CoA:amino acid N-acyltransferase functions in the conjugation of fatty acids to glycine. J. Biol. Chem. 278, 34237–34244 10.1074/jbc.M300987200 [DOI] [PubMed] [Google Scholar]
  • 36.Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M.et al. (2003) A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435–9440 10.1074/jbc.M209706200 [DOI] [PubMed] [Google Scholar]
  • 37.Pols T.W., Noriega L.G., Nomura M., Auwerx J. and Schoonjans K. (2011) The bile acid membrane receptor TGR5: a valuable metabolic target. Dig. Dis. 29, 37–44 10.1159/000324126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A.et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98, 3369–3374 10.1073/pnas.051551698 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M.et al. (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313–1316 10.1126/science.1070477 [DOI] [PubMed] [Google Scholar]
  • 40.Guo G.L., Lambert G., Negishi M., Ward J.M., Brewer H.B. Jr, Kliewer S.A.et al. (2003) Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278, 45062–45071 10.1074/jbc.M307145200 [DOI] [PubMed] [Google Scholar]
  • 41.Duboc H., Tache Y. and Hofmann A.F. (2014) The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig. Liver Dis. 46, 302–312 10.1016/j.dld.2013.10.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Guo C., Chen W.D. and Wang Y.D. (2016) TGR5, not only a metabolic regulator. Front. Physiol. 7, 646 10.3389/fphys.2016.00646 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Wang H., Chen J., Hollister K., Sowers L.C. and Forman B.M. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543–553 10.1016/S1097-2765(00)80348-2 [DOI] [PubMed] [Google Scholar]
  • 44.Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G. and Gonzalez F.J. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731–744 10.1016/S0092-8674(00)00062-3 [DOI] [PubMed] [Google Scholar]
  • 45.Downes M., Verdecia M.A., Roecker A.J., Hughes R., Hogenesch J.B., Kast-Woelbern H.R.et al. (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079–1092 10.1016/S1097-2765(03)00104-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mi L.Z., Devarakonda S., Harp J.M., Han Q., Pellicciari R., Willson T.M.et al. (2003) Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11, 1093–1100 10.1016/S1097-2765(03)00112-6 [DOI] [PubMed] [Google Scholar]
  • 47.Kalaany N.Y. and Mangelsdorf D.J. (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68, 159–191 10.1146/annurev.physiol.68.033104.152158 [DOI] [PubMed] [Google Scholar]
  • 48.Calkin A.C. and Tontonoz P. (2012) Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13, 213–224 10.1038/nrm3312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Kliewer S.A. and Mangelsdorf D.J. (2015) Bile acids as hormones: the FXR-FGF15/19 pathway. Dig. Dis. 33, 327–331 10.1159/000371670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Chong H.K., Biesinger J., Seo Y.K., Xie X. and Osborne T.F. (2012) Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR. BMC Genomics 13, 51 10.1186/1471-2164-13-51 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B.et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517–526 10.1016/S1097-2765(00)00051-4 [DOI] [PubMed] [Google Scholar]
  • 52.Hang S., Paik D., Yao L., Kim E., Trinath J., Lu J.et al. (2019) Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576, 143–148 10.1038/s41586-019-1785-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Song X., Sun X., Oh S.F., Wu M., Zhang Y., Zheng W.et al. (2020) Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature 577, 410–415 10.1038/s41586-019-1865-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Flint H.J., Scott K.P., Louis P. and Duncan S.H. (2012) The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol. Hepatol. 9, 577–589 10.1038/nrgastro.2012.156 [DOI] [PubMed] [Google Scholar]
  • 55.Valdes A.M., Walter J., Segal E. and Spector T.D. (2018) Role of the gut microbiota in nutrition and health. BMJ 361, k2179 10.1136/bmj.k2179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Gustafsson B.E., Gustafsson J.A. and Sjovall J. (1966) Intestinal and fecal sterols in germfree and conventional rats. Bile acids and steroids 172. Acta Chem. Scand. 20, 1827–1835 10.3891/acta.chem.scand.20-1827 [DOI] [PubMed] [Google Scholar]
  • 57.Hayakawa S. (1973) Microbiological transformation of bile acids. Adv. Lipid. Res. 11, 143–192 10.1016/B978-0-12-024911-4.50011-8 [DOI] [PubMed] [Google Scholar]
  • 58.Ridlon J.M., Kang D.J., Hylemon P.B. and Bajaj J.S. (2014) Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332–338 10.1097/MOG.0000000000000057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Cho I. and Blaser M.J. (2012) The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 10.1038/nrg3182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Hirano S. and Masuda N. (1981) Transformation of bile acids by Eubacterium lentum. Appl. Environ. Microbiol. 42, 912–915 10.1128/aem.42.5.912-915.1981 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Chikai T., Nakao H. and Uchida K. (1987) Deconjugation of bile acids by human intestinal bacteria implanted in germ-free rats. Lipids 22, 669–671 10.1007/BF02533948 [DOI] [PubMed] [Google Scholar]
  • 62.Midtvedt T. (1974) Microbial bile acid transformation. Am. J. Clin. Nutr. 27, 1341–1347 10.1093/ajcn/27.11.1341 [DOI] [PubMed] [Google Scholar]
  • 63.Wahlstrom A., Sayin S.I., Marschall H.U. and Backhed F. (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 10.1016/j.cmet.2016.05.005 [DOI] [PubMed] [Google Scholar]
  • 64.Funabashi M., Grove T.L., Wang M., Varma Y., McFadden M.E., Brown L.C.et al. (2020) A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582, 566–570 10.1038/s41586-020-2396-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Floch M.H., Binder H.J., Filburn B. and Gershengoren W. (1972) The effect of bile acids on intestinal microflora. Am. J. Clin. Nutr. 25, 1418–1426 10.1093/ajcn/25.12.1418 [DOI] [PubMed] [Google Scholar]
  • 66.Vernocchi P., Del Chierico F. and Putignani L. (2020) Gut microbiota metabolism and interaction with food components. Int. J. Mol. Sci. 21, 3688 10.3390/ijms21103688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Albenberg L.G., Lewis J.D. and Wu G.D. (2012) Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr. Opin. Gastroenterol. 28, 314–320 10.1097/MOG.0b013e328354586f [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Rapozo D.C., Bernardazzi C. and de Souza H.S. (2017) Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World J. Gastroenterol. 23, 2124–2140 10.3748/wjg.v23.i12.2124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Belkaid Y. and Hand T.W. (2014) Role of the microbiota in immunity and inflammation. Cell 157, 121–141 10.1016/j.cell.2014.03.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Lazar V., Ditu L.M., Pircalabioru G.G., Gheorghe I., Curutiu C., Holban A.M.et al. (2018) Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front. Immunol. 9, 1830 10.3389/fimmu.2018.01830 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Friedman E.S., Li Y., Shen T.D., Jiang J., Chau L., Adorini L.et al. (2018) FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid. Gastroenterology 155, 1741.e5–1752.e5 10.1053/j.gastro.2018.08.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Khan I., Ullah N., Zha L., Bai Y., Khan A., Zhao T.et al. (2019) Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens 8, 126 10.3390/pathogens8030126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Alam M.T., Amos G.C.A., Murphy A.R.J., Murch S., Wellington E.M.H. and Arasaradnam R.P. (2020) Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 12, 1 10.1186/s13099-019-0341-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Tiratterra E., Franco P., Porru E., Katsanos K.H., Christodoulou D.K. and Roda G. (2018) Role of bile acids in inflammatory bowel disease. Ann. Gastroenterol. 31, 266–272 10.20524/aog.2018.0239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Winston J.A. and Theriot C.M. (2020) Diversification of host bile acids by members of the gut microbiota. Gut Microbes 11, 158–171 10.1080/19490976.2019.1674124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Quinn R.A., Melnik A.V., Vrbanac A., Fu T., Patras K.A., Christy M.P.et al. (2020) Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579, 123–129 10.1038/s41586-020-2047-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S.et al. (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 98, 3375–3380 10.1073/pnas.051014398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Li T. and Chiang J.Y. (2005) Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G74–G84 10.1152/ajpgi.00258.2004 [DOI] [PubMed] [Google Scholar]
  • 79.Schmidt D.R., Holmstrom S.R., Fon Tacer K., Bookout A.L., Kliewer S.A. and Mangelsdorf D.J. (2010) Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486–14494 10.1074/jbc.M110.116004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D.et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328, 469–477 10.1124/jpet.108.145409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Yu J., Li S., Guo J., Xu Z., Zheng J. and Sun X. (2020) Farnesoid X receptor antagonizes Wnt/beta-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 11, 640 10.1038/s41419-020-02819-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Bailey A.M., Zhan L., Maru D., Shureiqi I., Pickering C.R., Kiriakova G.et al. (2014) FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G48–G58 10.1152/ajpgi.00234.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Phelan J.P., Reen F.J., Caparros-Martin J.A., O’Connor R. and O’Gara F. (2017) Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget 8, 115736–115747 10.18632/oncotarget.22803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Ajouz H., Mukherji D. and Shamseddine A. (2014) Secondary bile acids: an underrecognized cause of colon cancer. World J. Surg. Oncol. 12, 164 10.1186/1477-7819-12-164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Di Ciaula A., Wang D.Q., Molina-Molina E., Lunardi Baccetto R., Calamita G., Palmieri V.O.et al. (2017) Bile acids and cancer: direct and environmental-dependent effects. Ann. Hepatol. 16, s87–s105 10.5604/01.3001.0010.5501 [DOI] [PubMed] [Google Scholar]
  • 86.Nguyen T.T., Ung T.T., Kim N.H. and Jung Y.D. (2018) Role of bile acids in colon carcinogenesis. World J. Clin. Cases 6, 577–588 10.12998/wjcc.v6.i13.577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Ocvirk S. and O’Keefe S.J. (2017) Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet - gut microbiota interactions. Curr. Nutr. Rep. 6, 315–322 10.1007/s13668-017-0219-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Fu T., Coulter S., Yoshihara E., Oh T.G., Fang S., Cayabyab F.et al. (2019)FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098.e18–1112.e18 10.1016/j.cell.2019.01.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Terzic J., Grivennikov S., Karin E. and Karin M. (2010) Inflammation and colon cancer. Gastroenterology 138, 2101e5–2114e5 10.1053/j.gastro.2010.01.058 [DOI] [PubMed] [Google Scholar]
  • 90.Wu H.J. and Wu E. (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3, 4–14 10.4161/gmic.19320 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Belkaid Y. and Harrison O.J. (2017) Homeostatic immunity and the microbiota. Immunity 46, 562–576 10.1016/j.immuni.2017.04.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Fiorucci S., Biagioli M., Zampella A. and Distrutti E. (2018) Bile acids activated receptors regulate innate immunity. Front. Immunol. 9, 1853 10.3389/fimmu.2018.01853 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Heng T.S., Painter M.W. and Immunological Genome Project Consortium (2008) The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091–1094 10.1038/ni1008-1091 [DOI] [PubMed] [Google Scholar]
  • 94.Jia W., Xie G. and Jia W. (2018) Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev. Gastroenterol. Hepatol. 15, 111–128 10.1038/nrgastro.2017.119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Wilson A., Almousa A., Teft W.A. and Kim R.B. (2020) Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease. Sci. Rep. 10, 1866 10.1038/s41598-020-58644-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Fiorucci S., Carino A., Baldoni M., Santucci L., Costanzi E., Graziosi L.et al. (2021) Bile acid signaling in inflammatory bowel diseases. Dig. Dis. Sci. 66, 674–693 10.1007/s10620-020-06715-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Sinha S.R., Haileselassie Y., Nguyen L.P., Tropini C., Wang M., Becker L.S.et al. (2020) Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27, 659.e5–670.e5 10.1016/j.chom.2020.01.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Xu M., Cen M., Shen Y., Zhu Y., Cheng F., Tang L.et al. (2021) Deoxycholic acid-induced gut dysbiosis disrupts bile acid enterohepatic circulation and promotes intestinal inflammation. Dig. Dis. Sci. 66, 568–576 10.1007/s10620-020-06208-3 [DOI] [PubMed] [Google Scholar]
  • 99.Cao H., Xu M., Dong W., Deng B., Wang S., Zhang Y.et al. (2017) Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int. J. Cancer 140, 2545–2556 10.1002/ijc.30643 [DOI] [PubMed] [Google Scholar]
  • 100.Campbell C., McKenney P.T., Konstantinovsky D., Isaeva O.I., Schizas M., Verter J.et al. (2020) Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475–479 10.1038/s41586-020-2193-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Chen M.L., Huang X., Wang H., Hegner C., Liu Y., Shang J.et al. (2021) CAR directs T cell adaptation to bile acids in the small intestine. Nature 593, 147–151 10.1038/s41586-021-03421-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Fu T. and Evans R. (2020) Abstract 396: The bile acid receptor FXR suppress colitis-induced colon cancer. Cancer Res. 80, 396 10.1158/1538-7445.AM2020-396 [DOI] [Google Scholar]

Articles from Essays in Biochemistry are provided here courtesy of Portland Press Ltd

RESOURCES